ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
value factor · long-only model fund

Foundry RD Industry-Neutral Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FRDRHYPOTHETICAL MODEL
Since ’99
+140%
Expense Ratio
0.35%
placeholder
Holdings
105
cap-weighted
Inception
Oct 2020
placeholder
Full Sharpe
0.26
Ann. Return (LS)
5.3%
Ann. Volatility
20.8%
Max Drawdown
-56.3%
Test Sharpe ’19–26
-0.15
Test FF5 α (ann.)
-8.8%
vs Fama-French 5
Test FF5 α t-stat
-1.11
not significant
Monthly turnover
18%
of the long leg, per rebalance
Cumulative return (LS)
140%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.63
what this fund holds
Long leg ann. return
14.1%
buyable, long-only
Long-short Sharpe
0.26
requires shorting
Bottom bucket ann. return
8.8%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

105 of 105 · 100.0% of book
TickerCompanySectorMarket capWeight
1WAB
WESTINGHOUSE AIR BRAKE TECHNOLOGIES CORPIndustrials$44.47B
19.19%
2CNH
CNH INDUSTRIAL NVIndustrials$13.19B
5.69%
3ZBRA
ZEBRA TECHNOLOGIES CORPTechnology$12.74B
5.50%
4SWKS
SKYWORKS SOLUTIONS INCTechnology$8.93B
3.85%
5CHYM
CHIME FINANCIAL INCTechnology$8.51B
3.67%
6AGCO
AGCO CORPIndustrials$8.35B
3.60%
7MBLY
MOBILEYE GLOBAL INCConsumer Cyclical$7.76B
3.35%
8QRVO
QORVO INCTechnology$7.53B
3.25%
9OKLO
OKLO INCUtilities$7.15B
3.09%
10JOBY
JOBY AVIATION INCIndustrials$7.11B
3.07%
11OTEX
OPEN TEXT CORPTechnology$5.65B
2.44%
12MUR
MURPHY OIL CORPEnergy$5.28B
2.28%
13BC
BRUNSWICK CORPConsumer Cyclical$5.23B
2.26%
14GBTG
GLOBAL BUSINESS TRAVEL GROUP INCTechnology$4.91B
2.12%
15DLB
DOLBY LABORATORIES INCIndustrials$4.64B
2.00%
16UEC
URANIUM ENERGY CORPBasic Materials$4.59B
1.98%
17SYNA
SYNAPTICS INCTechnology$4.41B
1.90%
18BDC
BELDEN INCTechnology$3.95B
1.70%
19VECO
VEECO INSTRUMENTS INCTechnology$3.19B
1.38%
20FLY
FIREFLY AEROSPACE INCIndustrials$3.09B
1.33%
21LCID
LUCID GROUP INCConsumer Cyclical$2.87B
1.24%
22UPST
UPSTART HOLDINGS INCFinancial Services$2.82B
1.22%
23VISN
VISTANCE NETWORKS INCTechnology$2.74B
1.18%
24AMBA
AMBARELLA INCTechnology$2.71B
1.17%
25CALX
CALIX INCTechnology$2.50B
1.08%
26PPTA
PERPETUA RESOURCES CORPBasic Materials$2.11B
0.91%
27VRDN
VIRIDIAN THERAPEUTICS INCHealthcare$1.86B
0.80%
28SRPT
SAREPTA THERAPEUTICS INCHealthcare$1.82B
0.78%
29SONO
SONOS INCTechnology$1.80B
0.78%
30ASAN
ASANA INCTechnology$1.77B
0.77%
31TDOC
TELADOC HEALTH INCHealthcare$1.70B
0.73%
32PLPC
PREFORMED LINE PRODUCTS COIndustrials$1.60B
0.69%
33ENOV
ENOVIS CORPIndustrials$1.56B
0.67%
34MLKN
MILLERKNOLL INCConsumer Cyclical$1.49B
0.64%
35FMC
FMC CORPBasic Materials$1.40B
0.60%
36WLTH
WEALTHFRONT CORPTechnology$1.38B
0.60%
37AI
C3AI INCTechnology$1.37B
0.59%
38NBR
NABORS INDUSTRIES LTDEnergy$1.24B
0.54%
39VYX
NCR VOYIX CORPTechnology$1.13B
0.49%
40CRTO
CRITEO SACommunication Services$1.13B
0.49%
41UPWK
UPWORK INCIndustrials$1.12B
0.48%
42EYPT
EYEPOINT INCHealthcare$1.12B
0.48%
43MUX
MCEWEN INCBasic Materials$978M
0.42%
44ADTN
ADTRAN HOLDINGS INCTechnology$944M
0.41%
45AOSL
ALPHA & OMEGA SEMICONDUCTOR LTDTechnology$936M
0.40%
46HPK
HIGHPEAK ENERGY INCEnergy$931M
0.40%
47TDUP
THREDUP INCConsumer Cyclical$852M
0.37%
48NNE
NANO NUCLEAR ENERGY INCIndustrials$835M
0.36%
49RPD
RAPID7 INCTechnology$815M
0.35%
50PD
PAGERDUTY INCTechnology$794M
0.34%
51PAR
PAR TECHNOLOGY CORPTechnology$674M
0.29%
52CARS
CARSCOM INCConsumer Cyclical$670M
0.29%
53PHR
PHREESIA INCHealthcare$662M
0.29%
54TREE
LENDINGTREE INCFinancial Services$645M
0.28%
55NTGR
NETGEAR INCTechnology$602M
0.26%
56EGY
VAALCO ENERGY INCEnergy$553M
0.24%
57YEXT
YEXT INCTechnology$535M
0.23%
58SPT
SPROUT SOCIAL INCTechnology$518M
0.22%
59ARVN
ARVINAS INCHealthcare$517M
0.22%
60RGNX
REGENXBIO INCHealthcare$511M
0.22%
61TWI
TITAN INTERNATIONAL INCIndustrials$493M
0.21%
62SPIR
SPIRE GLOBAL INCIndustrials$488M
0.21%
63VREX
VAREX IMAGING CORPHealthcare$444M
0.19%
64CMCO
COLUMBUS MCKINNON CORPIndustrials$414M
0.18%
65CRNC
CERENCE INCTechnology$390M
0.17%
66BBBY
BED BATH & BEYOND INCConsumer Cyclical$372M
0.16%
67XPER
XPERI INCTechnology$352M
0.15%
68VELO
VELO3D INCTechnology$316M
0.14%
69LYEL
LYELL IMMUNOPHARMA INCHealthcare$311M
0.13%
70SSTK
SHUTTERSTOCK INCCommunication Services$272M
0.12%
71AVNW
AVIAT NETWORKS INCTechnology$269M
0.12%
72TRDA
ENTRADA THERAPEUTICS INCHealthcare$268M
0.12%
73ANGI
ANGI INCCommunication Services$248M
0.11%
74UP
WHEELS UP EXPERIENCE INCIndustrials$229M
0.10%
75SPOK
SPOK HOLDINGS INCHealthcare$222M
0.10%
76KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
0.09%
77SENS
SENSEONICS HOLDINGS INCHealthcare$214M
0.09%
78KROS
KEROS THERAPEUTICS INCHealthcare$211M
0.09%
79GSIT
GSI TECHNOLOGY INCTechnology$208M
0.09%
80AIRO
AIRO GROUP HOLDINGS INCIndustrials$205M
0.09%
81AMWL
AMERICAN WELL CORPHealthcare$199M
0.09%
82SRI
STONERIDGE INCConsumer Cyclical$197M
0.08%
83EGAN
EGAIN CORPTechnology$180M
0.08%
84ARCT
ARCTURUS THERAPEUTICS HOLDINGS INCHealthcare$172M
0.07%
85EXOD
EXODUS MOVEMENT INCTechnology$152M
0.07%
86CHPT
CHARGEPOINT HOLDINGS INCConsumer Cyclical$146M
0.06%
87DMRC
DIGIMARC CORPTechnology$133M
0.06%
88FIRY
FIRY INCTechnology$130M
0.06%
89AARD
AARDVARK THERAPEUTICS INCHealthcare$128M
0.06%
90INSG
INSEEGO CORPTechnology$122M
0.05%
91TCX
TUCOWS INCTechnology$114M
0.05%
92SCOR
COMSCORE INCCommunication Services$113M
0.05%
93USGO
US GOLDMINING INCBasic Materials$109M
0.05%
94GEOS
GEOSPACE TECHNOLOGIES CORPEnergy$88M
0.04%
95NTIC
NORTHERN TECHNOLOGIES INTERNATIONAL CORPBasic Materials$77M
0.03%
96ACET
ADICET BIO INCHealthcare$76M
0.03%
97AIRG
AIRGAIN INCTechnology$76M
0.03%
98BODI
BEACHBODY COMPANY INCCommunication Services$75M
0.03%
99IMA
IMAGENEBIO INCHealthcare$61M
0.03%
100SKIL
SKILLSOFT CORPConsumer Defensive$58M
0.02%
101LNZA
LANZATECH GLOBAL INCIndustrials$56M
0.02%
102STEM
STEM INCTechnology$56M
0.02%
103TACT
TRANSACT TECHNOLOGIES INCTechnology$54M
0.02%
104XLO
XILIO THERAPEUTICS INCHealthcare$53M
0.02%
105MCRB
SERES THERAPEUTICS INCHealthcare$52M
0.02%

Full long-leg book as of July 2026 · cap-weighted · total market cap $231.71B. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

10 sectors
Industrials
37.9%
Technology
36.1%
Consumer Cyclical
8.5%
Healthcare
4.7%
Basic Materials
4.0%
Energy
3.5%
Utilities
3.1%
Financial Services
1.5%
Communication Services
0.8%
Consumer Defensive
0.0%

Portfolio Style

Size × value map of the long-leg book

105 classified
Value
Blend
Growth
Large
Mid
Small
2%1
32%9
27%3
6%10
7%8
15%12
3%28
2%12
1%7

Share of long-leg capital by market cap × book-to-market, using terciles of the 3,283-name universe at July 2026. Rows: Large ≥ $5.2B, Small < $819M. Columns: Value ≥ 0.62, Growth < 0.34 B/M. The dot marks the capital-weighted centroid of the book — 79% toward Large, 66% toward Growth. +5% unclassified (15 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt79% → Large
SmallLarge
Value ↔ growth tilt66% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 105 names now. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
4
Failed
1
Not tested
2
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

2 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • Days required to liquidate the largest position at 20% of one day's dollar volume.

    Required
    <= 7.0 days
    Actual
    7.9 days
    Margin
    -0.9 days
Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 105 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.4 (95% CI 1.3-1.8)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
13.9%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
1.45x
within
parametric
1.41x
within
cornish fisher
1.51x
within

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2001
Before publication (pre-2001)
0.81
Sharpe · 27.4% p.a.
January 1999December 2001 · 36 mo
Since publication
0.14
Sharpe · 2.6% p.a.
January 2002July 2026 · 295 mo
Change in Sharpe−0.67Sharpe weakened since publication90% of the prior annual return given up

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
54%
14 of 26 3-year windows made money
Worst window
-0.92
Sharpe, January 2014 – December 2016
January 1999July 2026
Median Sharpe
0.20
Dispersion
0.56
Best window
1.18

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.36.4%0.2%
3 yearsp.a.17.8%3.7%
5 yearsp.a.7.5%-1.6%
10 yearsp.a.15.0%-0.4%
Since inceptionp.a.12.2%3.2%
Calendar years
YearLong legLong-short
20267 mo19.6%8.5%
202536.6%9.5%
20245.1%3.7%
2023-1.1%-4.6%
2022-12.3%-12.5%
202123.7%-6.0%
20205.1%-14.2%
201917.4%-23.3%
20187.3%28.8%
201748.9%13.3%
201619.2%-10.5%
2015-2.8%-4.7%
20141.5%-14.3%
201349.0%12.3%
201213.3%2.3%
2011-9.0%-9.9%
201036.5%33.3%
200944.7%16.9%
2008-51.7%-42.4%
200716.0%10.3%
200624.4%13.7%
200524.1%16.6%
200422.9%8.0%
200348.0%20.4%
2002-20.9%3.4%
2001-16.8%7.1%
200024.3%52.3%
199945.0%18.5%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FRDR
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.35% (placeholder)
Inception2020-10-21 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$231.71B

Methodology

The Foundry RD Industry-Neutral Factor ETF tracks a rules-based model that ranks liquid U.S. common stocks, industry-neutralized within Fama-French industries, each month by a RD signal and holds the top decile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.